Mitra Neiafar, Fatemeh Esfahanian, Alireza Esteghamati, Ramin Heshmat, Mehdi Hedayati, Masoumeh Karami, Mehrshad Abbasi, Manochehr Nakhjavani,
Volume 4, Issue 4 (17 2005)
Abstract
Background: Oxidized low-density lipoprotein (Ox-LDL), a key factor in the development of atherosclerosis, can cause endothelial dysfunction and augment lipid accumulation within the arterial wall. Increased oxidative stress in diabetes contributes to this process. Ox-LDL is a highly immunogenic molecule and it is not clear whether anti oxidized LDL antibodies (OLAB) are pathogenic or protective in atherosclerosis? The aim of this study was to evaluate Ox-LDL and its antibody in type 2 diabetes and healthy subjects.
Methods: As a case-control study we evaluated 81 type 2 diabetic patients and 69 non-diabetic healthy persons aged 40 to 65 years. Controls were sex and BMI matched with diabetic patients. Patients with history of cigarette smoking, antioxidant or antihyperlipidemic drugs consumption, coronary heart disease, hypertension , and renal impairment were excluded. We measured serum level of Ox-LDL(two monoclonal antibody of Mercodia co.) and OLAB by ELISA. Lipid profile, serum electrolytes, and HbA1c (HPLC) were also determined. Ox-LDL and its antibody were compared between diabetic patients and controls and the correlation with lipid profile, HbA1c and BMI were assessed.
Results: Serum Ox-LDL concentration and Ox-LDL to LDL ratio were distinctively higher in controls (15.7+-6.9 vs. 11.8+-5.6, P < 0.005). Ox-LDL concentrations were correlated with LDL-C (rs=0.36, P<0.0005) and total cholesterol (rs=0.31, P<0.0005) in both groups but not with age and HbA1c. In diabetic patients, Ox-LDL and its antibody were positively correlated (rs=0.26, P<0.05). Obese diabetic patients (BMI > 30) had higher Ox-LDL concentrations in comparison with diabetic patients with BMI less than 30.
Conclusion: In diabetic patients Ox-LDL level is lower than non-diabetics and is correlated with its antibodies. Based on previous findings, we suppose that the pattern of LDL oxidation enhances Ox-LDL recognition by macrophage via specific legends. This results in low serum Ox-LDL concentrations in diabetes.
Azam Karami Paskohani, Masoud Rahmati , Abdolreza Kazemi ,
Volume 14, Issue 3 (3-2015)
Abstract
Background: Diabetic neuropathy leads to skeletal muscle atrophy however atrophy signaling mechanisms are not well documented. The aim of the present study was to investigate Sunday Driver (Syd) gene expression in soleus muscle of Wistar male rats with diabetic neuropathy. Methods: Twelve male Wistar rats were randomly assigned in 3 groups: diabetic trained, diabetic untrained and healthy control. Two weeks after STZ injection (45 mg/Kg), diabetic neuropathy was demonstrated with mechanical allodynia and thermal hyperalgesia tests and after which moderate endurance training protocol was performed for 6 weeks. 48 hours after final training session, the rats were dissected and soleus muscle tissues were removed. Also Sydgene expression was measured with Real time- PCR methods. Results: Soleus muscle weight was decreased in diabetic groups (P=0.001), but compared with diabetic untrained group, was higher in diabetic trained group (P=0.001). Sydgene expression in diabetic untrained group was higher than healthy control group (P=0.001). Also, compared with diabetic untrained group, training significantly decreased Sydgene expression and blood glucose levels in diabetic trained group. (P=0.001 and P=0.0001, respectively). Conclusion: In soleus muscle of diabetic rats, Sydm RNAup-regulation is involved in development of muscle atrophy and training as a non-pharmacotherapy strategy can modulate and get it close to normal levels. So, it is suggested that Syd should be noted as a novel treatment in diabetes disease.
